These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 7684012)

  • 21. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
    Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
    J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Rescue treatment in Hodgkin's disease].
    Zori Comba A; Koziner B
    Sangre (Barc); 1987; 32(1):67-76. PubMed ID: 2438788
    [No Abstract]   [Full Text] [Related]  

  • 23. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
    Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
    J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
    Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
    Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease.
    Gobbi PG; Broglia C; Bertè R; Petrilli MP; Molica S; Angrilli F; Iannitto E; Ghirardelli ML; Di Renzo N; Cavanna L; Ascari E
    Haematologica; 2000 Jul; 85(7):722-8. PubMed ID: 10897124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation.
    Chow LM; Nathan PC; Hodgson DC; Jenkin D; Weitzman S; Grant RM; Manson D; Bross A; Doyle JJ; Danjoux C; Greenberg ML
    J Clin Oncol; 2006 Dec; 24(36):5735-41. PubMed ID: 17179107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MOPP, ABVD, or both to treat Hodgkin's disease.
    Aisenberg AC
    N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680765
    [No Abstract]   [Full Text] [Related]  

  • 28. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy.
    Straus DJ; Gaynor JJ; Myers J; Merke DP; Caravelli J; Chapman D; Yahalom J; Clarkson BD
    J Clin Oncol; 1990 Jul; 8(7):1173-86. PubMed ID: 1694235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease.
    Aglietta M; Montemurro F; Fagioli F; Volta C; Botto B; Cantonetti M; Racanelli V; Teofili L; Ferrara R; Amadori S; Castoldi GL; Dammacco F; Levis A
    Cancer; 2000 Jan; 88(2):454-60. PubMed ID: 10640980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The management of Hodgkin's disease with chemotherapy or combined modality treatment].
    Tsushita K; Utsumi M; Shimoyama M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2202-9. PubMed ID: 9881076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to chemotherapy in aggressive non-Hodgkin's lymphomas.
    Gerhartz HH; Engelhard M; Brittinger G; Schlimok G; Thiel E; Huber C; Emmerich B; Schadek C; Brandmaier R; Stern AC
    Semin Oncol; 1994 Dec; 21(6 Suppl 16):25-8. PubMed ID: 7528447
    [No Abstract]   [Full Text] [Related]  

  • 32. Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute.
    Bonadonna G; Viviani S; Bonfante V; Gianni AM; Valagussa P
    Eur J Cancer; 2005 May; 41(7):998-1006. PubMed ID: 15862748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Granulocyte colony stimulating factor (G-CSF) as adjunct therapy in relapsed-resistant high-grade non-Hodgkin's lymphoma.
    Zinzani PL; Martelli M; Tura S; Mandelli F
    Haematologica; 1993; 78(1):40-3. PubMed ID: 7684011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical study of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced leukopenia].
    Shi YK; Sun Y; Su M
    Zhonghua Zhong Liu Za Zhi; 1994 Sep; 16(5):356-9. PubMed ID: 7895587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AIDS Clinical Trials Group Study 094: a phase I/II trial of ABV chemotherapy with zidovudine and recombinant human GM-CSF in AIDS-related Kaposi's sarcoma.
    Gill PS; Mitsuyasu RT; Montgomery T; Huang J; Cabriales S; Testa M; Espina BM; Levine AM; Miles SA
    Cancer J Sci Am; 1997; 3(5):278-83. PubMed ID: 9327151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pediatric Hodgkin's disease.
    Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
    J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of advanced Hodgkin's disease with chemotherapy and irradiation. Controlled trial of two versus three alternating, potentially non-cross-resistant drug combinations.
    Straus DJ; Myers J; Lee BJ; Nisce LZ; Koziner B; McCormick B; Kempin S; Mertelsmann R; Arlin Z; Gee T
    Am J Med; 1984 Feb; 76(2):270-8. PubMed ID: 6198910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy of lomustine, teniposide, doxorubicin, bleomycin and prednisone (LTABP) or adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) in the treatment of malignant lymphogranulomatosis resistant to MOPP].
    Robak T; Krykowski E; Płuzańska A; Olszańska-Skorek T; Kowalczyński M; Urbańska-Ryś H
    Pol Tyg Lek; 1990 May 21-28; 45(21-22):426-9. PubMed ID: 1702536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
    Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN; Dimopoulou MN; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Karkantaris C; Anargyrou K; Boutsis DE; Variamis E; Michalopoulos T; Boussiotis VA; Panayiotidis P; Papavassiliou C; Pangalis GA
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):765-81. PubMed ID: 15183480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
    Andrieu JM; Colonna P
    J Clin Oncol; 1998 Jun; 16(6):2283. PubMed ID: 9626234
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.